221 related articles for article (PubMed ID: 9415629)
1. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
Criswell LA; Such CL; Yelin EH
J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
[TBL] [Abstract][Full Text] [Related]
2. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?
Criswell LA; Henke CJ
J Rheumatol; 1995 May; 22(5):829-35. PubMed ID: 8587068
[TBL] [Abstract][Full Text] [Related]
3. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
Pope JE; Hong P; Koehler BE
J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
[TBL] [Abstract][Full Text] [Related]
4. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.
Maetzel A; Bombardier C; Strand V; Tugwell P; Wells G
J Rheumatol; 1998 Dec; 25(12):2331-8. PubMed ID: 9858426
[TBL] [Abstract][Full Text] [Related]
5. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
Zink A; Listing J; Ziemer S; Zeidler H;
J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
[TBL] [Abstract][Full Text] [Related]
6. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
[TBL] [Abstract][Full Text] [Related]
7. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
8. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
Galindo-Rodriguez G; Avina-Zubieta JA; Fitzgerald A; LeClerq SA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
10. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness.
Suarez-Almazor ME; Soskolne CL; Saunders LD; Russell AS
J Rheumatol; 1995 May; 22(5):836-43. PubMed ID: 8587069
[TBL] [Abstract][Full Text] [Related]
11. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
12. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
13. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
14. How do French rheumatologists treat early rheumatoid arthritis?
de Asit N; Le Loët X; Czernichow P; Bertho JM; Delcambre B; Tonnel F; Loyau G; Dapogny C; Trèves R; Valat JP; Tauveron P; Sebert JL; Boumier P
Rev Rhum Engl Ed; 1996 Mar; 63(3):188-95. PubMed ID: 8731236
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
16. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
[TBL] [Abstract][Full Text] [Related]
17. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
Hoekstra M; van de Laar MA; Bernelot Moens HJ; Kruijsen MW; Haagsma CJ
J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
[TBL] [Abstract][Full Text] [Related]
18. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
Lacaille D; Stein HB; Raboud J; Klinkhoff AV
J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
20. Variation among rheumatologists in clinical outcomes and frequency of office visits for rheumatoid arthritis.
Criswell LA; Such CL; Neuhaus JM; Yelin EH
J Rheumatol; 1997 Jul; 24(7):1266-71. PubMed ID: 9228122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
